Evidence map›Paper›PMID 37428201›Full record

ArticleAnnals of hematology2023

Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML).

Alexander Pohlmann, Eva Bentgens, Christoph Schülke, David Kuron, Christian Reicherts, Julia Marx, Linus Angenendt, Jan-Henrik Mikesch, Georg Lenz, Matthias Stelljes and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Annals of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Alexander Pohlmann *Department of Medicine A, University Hospital Münster, Münster, Germany. alexander.pohlmann@ukmuenster.de.ORCID http://orcid.org/0000-0003-4003-5884
Eva Bentgens *Department of Medicine A, University Hospital Münster, Münster, Germany.
Christoph SchülkeDepartment of Clinical Radiology, University Hospital Münster, Münster, Germany.
David KuronDepartment of Medicine II, University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
Christian ReichertsDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Julia MarxDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Linus AngenendtDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Jan-Henrik MikeschDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Georg LenzDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Matthias StelljesDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Christoph SchliemannDepartment of Medicine A, University Hospital Münster, Münster, Germany.
University Hospital Münster · DEUniversity Hospital Schleswig-Holstein · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment modality for patients with acute myeloid leukemia (AML). Here, we investigated the predictive value of spleen volume on outcome parameters and engraftment kinetics after HSCT in a large cohort of AML patients. A total of 402 patients who received their first HSCT between January 2012 and March 2019 were included in this retrospective study. Spleen volume was correlated to clinical outcome and engraftment kinetics. Median follow-up was 33.7 months (95% confidence interval [CI], 28.9-37.4 months). Patients were subdivided based on median spleen volume of 238.0 cm

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteHumansRetrospective StudiesSpleenSplenomegalyTransplantation ConditioningAcute myeloid leukemiaEngraftmentHematopoietic stem cell transplantationNon-relapse mortalitySpleen volume

Identifiers

PMID37428201
PMCPMC10444671
OpenAlexW4383710036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.